HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

RIBOLIFE-B

53.200

-2.550-4.57%

Volume:112.66K

Turnover:6.10M

Market Cap:9.07B

PE:-25.33

High:58.000

Open:56.500

Low:52.650

Close:55.750

52wk High:95.800

52wk Low:51.200

Shares:170.55M

HK Float Shares:170.55M

Volume Ratio:0.80

T/O Rate:0.07%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-2.100

ROE:--

ROA:-23.42%

PB:-83.69

PE(LYR):-25.33

PS:52.94

Loading ...

Overview Company News Filings

RIBOLIFE Shareholders Approve All 2025 AGM Resolutions, Including H-Share Incentive Schemes and Articles Amendments

Bulletin Express

Suzhou Ribo shareholders back 2026 directors’ remuneration plan at AGM

Suzhou Ribo submits EMA Phase 2 trial application for RBD1119 in coronary artery disease

Ribo Announces Phase 2 Clinical Trial Submission to Ema, Further Advancing Sirna Therapeutics in Thromboembolic Disease

THOMSON REUTERS

Suzhou Ribo Seeks Coronary Artery Disease Drug Trial in Europe

MT Newswires Live

RIBOLIFE-B (06938) Files Phase II Clinical Trial Application for RBD1119 Injection in Coronary Artery Disease Treatment

Ribo Life Science submits Phase II clinical trial application for RBD1119 Injection targeting coronary artery disease

Bulletin Express

Soochow Securities Reiterates "Buy" Rating on RIBOLIFE-B (06938) Citing Advancements in Extrabepatic Delivery Technology

Registration Open for "Zhihui Financial 2026 Summer Roadshow Conference"

Ribo signs strategic collaboration with Insilico Medicine on AI-driven siRNA drugs

Insilico Medicine partners with Ribo Life Science on AI-driven oligonucleotide R&D

Ribo Announces Strategic Collaboration With Insilico Medicine to Accelerate Sirna Drug Development Driven by AI

THOMSON REUTERS

瑞博生物发布H股股权激励方案：股份总量上限17.06 million，占总股本10%

Bulletin Express

瑞博生物发布H股购股权计划：期权总量上限约1,705.55万股，占已发行股本10%

Bulletin Express

RIBOLIFE-B Calls 5 June 2026 AGM; Tables Option & Incentive Schemes, Scraps Supervisory Committee and Seeks Fresh Mandates

Bulletin Express

Ribo Life Science releases proxy details for 2025 AGM; shareholders to vote on profit distribution, equity incentives and governance overhaul

Bulletin Express

Suzhou Ribo Life Science announces annual shareholder meeting rescheduling

Suzhou Ribo Seeks Venous Thromboembolism Drug Trial in Europe

MT Newswires Live

RIBOLIFE-B's Core Product Vortosiran Submits Phase 2b Clinical Trial Application for Venous Thromboembolism

RIBOLIFE-B Advances Core siRNA Therapy: Submits Phase 2b European Trial Application for Vortosiran in Venous Thromboembolism

Bulletin Express

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/06938/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"06938","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"06938\",,,,,undefined,":{"symbol":"06938","market":"HK","secType":"STK","nameCN":"RIBOLIFE-B","latestPrice":53.2,"timestamp":1780646950939,"preClose":55.75,"halted":0,"volume":112664,"delay":0,"changeRate":-0.045739910313901296,"floatShares":170554910,"shares":170554910,"eps":-2.100221,"marketStatus":"Market Closed","change":-2.55,"latestTime":"06-05 16:09:10","open":56.5,"high":58,"low":52.65,"amount":6104188,"amplitude":0.095964,"askPrice":53.25,"askSize":200,"bidPrice":52.75,"bidSize":200,"shortable":0,"etf":0,"ttmEps":-1.805,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1780882200000},"marketStatusCode":7,"adr":0,"listingDate":1767888000000,"exchange":"SEHK","adjPreClose":55.75,"openAndCloseTimeList":[[1780623000000,1780632000000],[1780635600000,1780646400000]],"volumeRatio":0.8034676384161319,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"06938\",,,,,undefined,":{"symbol":"06938","floatShares":170554910,"roa":"-23.42%","roe":"--","lyrEps":-2.100221,"volumeRatio":0.8034676384161319,"shares":170554910,"dividePrice":0,"high":58,"amplitude":0.095964,"preClose":55.75,"low":52.65,"week52Low":51.2,"pbRate":"-83.69","psRate":"52.94","week52High":95.8,"institutionHeld":0,"latestPrice":53.2,"eps":-2.100221,"divideRate":0,"volume":112664,"delay":0,"ttmEps":-1.805,"open":56.5,"prevYearClose":57.97,"prevWeekClose":58.2,"prevMonthClose":58.2,"prevQuarterClose":57.3,"fiveDayClose":58.2,"twentyDayClose":61,"sixtyDayClose":60.25},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/06938\",params:#limit:5,,,undefined,":[{"market":"HK","date":"2026-03-25","symbol":"06938","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1774368000000,"reportTimeType":"post","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"06938\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"06938\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0.5,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5,"analysts":4,"updateTime":1779465600000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/06938\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"06938","date":"2026-06-04","current":-29.473684,"percent":0.972222,"low":-50.513246,"twenty":-40.072106,"median":-35.241421,"eighty":-30.912395,"high":-28.84909,"avg":-36.264942,"sd":5.818002,"marketCap":9508436232},"quantilePoints":[{"date":"2026-02-13","current":-47.784644,"twenty":-49.967526,"median":-49.148945,"eighty":-48.330365,"marketCap":11947371445},{"date":"2026-02-20","current":-49.493094,"twenty":-49.901155,"median":-49.02522,"eighty":-48.248265,"marketCap":12356703229},{"date":"2026-02-27","current":-46.28708,"twenty":-49.778496,"median":-48.557346,"eighty":-47.185619,"marketCap":11683011335},{"date":"2026-03-06","current":-41.043234,"twenty":-48.963884,"median":-47.035862,"eighty":-41.420692,"marketCap":10275933327},{"date":"2026-03-13","current":-37.939269,"twenty":-48.578839,"median":-43.677981,"eighty":-39.627323,"marketCap":9542547214},{"date":"2026-03-20","current":-38.832211,"twenty":-48.543939,"median":-40.85279,"eighty":-39.405242,"marketCap":9730157615},{"date":"2026-03-27","current":-30.985978,"twenty":-48.084787,"median":-40.112534,"eighty":-38.372934,"marketCap":9755740852},{"date":"2026-04-02","current":-34.881193,"twenty":-47.185618,"median":-39.757485,"eighty":-36.526858,"marketCap":11034902677},{"date":"2026-04-10","current":-37.770699,"twenty":-46.28708,"median":-39.613953,"eighty":-36.479378,"marketCap":12041176646},{"date":"2026-04-17","current":-35.241421,"twenty":-45.408639,"median":-38.832211,"eighty":-35.918978,"marketCap":11239568569},{"date":"2026-04-24","current":-33.421304,"twenty":-43.677981,"median":-38.300657,"eighty":-35.241421,"marketCap":10659681875},{"date":"2026-04-30","current":-32.557368,"twenty":-42.07346,"median":-37.836456,"eighty":-34.614071,"marketCap":10386794019},{"date":"2026-05-08","current":-32.498031,"twenty":-41.169053,"median":-37.354591,"eighty":-33.058756,"marketCap":10403849510},{"date":"2026-05-15","current":-32.120533,"twenty":-40.738524,"median":-36.586666,"eighty":-32.493391,"marketCap":10310044309},{"date":"2026-05-22","current":-30.090442,"twenty":-40.591323,"median":-35.918978,"eighty":-32.095834,"marketCap":9636352415},{"date":"2026-05-29","current":-30.88841,"twenty":-40.296947,"median":-35.448939,"eighty":-31.691849,"marketCap":9926295762},{"date":"2026-06-04","current":-29.545245,"twenty":-40.072106,"median":-35.241421,"eighty":-30.912395,"marketCap":9508436232}],"updateTime":1780700332167},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"06938\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1165897219","title":"RIBOLIFE Shareholders Approve All 2025 AGM Resolutions, Including H-Share Incentive Schemes and Articles Amendments","url":"https://stock-news.laohu8.com/highlight/detail?id=1165897219","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1165897219?lang=en_us&edition=fundamental","pubTime":"2026-06-05 20:43","pubTimestamp":1780663380,"startTime":"0","endTime":"0","summary":"On 5 June 2026, Suzhou Ribo Life Science Co., Ltd. (RIBOLIFE) held its 2025 Annual General Meeting in Beijing. Shareholders representing 76.81 million H shares, or 45.04 % of the issued share...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641148556","title":"Suzhou Ribo shareholders back 2026 directors’ remuneration plan at AGM","url":"https://stock-news.laohu8.com/highlight/detail?id=2641148556","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641148556?lang=en_us&edition=fundamental","pubTime":"2026-06-05 20:33","pubTimestamp":1780662831,"startTime":"0","endTime":"0","summary":"Shareholders backed a 2026 directors’ remuneration plan, authorizing the board to set directors’ pay; 74,955,374 votes for, 1,858,075 abstained.Meeting also passed H Share Option Scheme, H Share Incentive Scheme, related limits; each drew 64,874,926 for, 7,640,899 against, 4,297,624 abstained.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Suzhou Ribo Life Science Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange  , on June 05, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260605:nNDL7grPcv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638065664","title":"Suzhou Ribo submits EMA Phase 2 trial application for RBD1119 in coronary artery disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2638065664","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638065664?lang=en_us&edition=fundamental","pubTime":"2026-05-28 10:52","pubTimestamp":1779936752,"startTime":"0","endTime":"0","summary":"Suzhou Ribo Life Science submitted a Phase 2 clinical trial application to the EMA for RBD1119, an siRNA candidate for coronary artery disease.The filing extends Ribo’s anticoagulation pipeline in thromboembolic disease, targeting improved efficacy with lower bleeding risk versus current therapies.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Suzhou Ribo Life Science Co. Ltd. published the original content used to generate this news brief via PR Newswire  on May 28, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260528:nNDL7wdZ80:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638616656","title":"Ribo Announces Phase 2 Clinical Trial Submission to Ema, Further Advancing Sirna Therapeutics in Thromboembolic Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2638616656","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638616656?lang=en_us&edition=fundamental","pubTime":"2026-05-28 10:51","pubTimestamp":1779936705,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260528:nTUA7QDPT6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["06938","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638653364","title":"Suzhou Ribo Seeks Coronary Artery Disease Drug Trial in Europe","url":"https://stock-news.laohu8.com/highlight/detail?id=2638653364","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638653364?lang=en_us&edition=fundamental","pubTime":"2026-05-28 09:33","pubTimestamp":1779932024,"startTime":"0","endTime":"0","summary":"Suzhou Ribo Life Science (HKG:6938) submitted a phase 2b clinical trial application for RBD1119 at the European Medicines Agency (EMA), according to a Thursday filing with the Hong Kong bourse.The trial aims to study the drug for the treatment of coronary artery disease.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["EMA","BK1161","BK4081","06938","BK7129","EMA.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123219623","title":"RIBOLIFE-B (06938) Files Phase II Clinical Trial Application for RBD1119 Injection in Coronary Artery Disease Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=1123219623","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1123219623?lang=en_us&edition=fundamental","pubTime":"2026-05-28 07:50","pubTimestamp":1779925820,"startTime":"0","endTime":"0","summary":"RIBOLIFE-B (06938) announced that it has successfully submitted a Phase II clinical trial application to the European Medicines Agency for its self-developed product, RBD1119 injection, intended for...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181474011","title":"Ribo Life Science submits Phase II clinical trial application for RBD1119 Injection targeting coronary artery disease","url":"https://stock-news.laohu8.com/highlight/detail?id=1181474011","media":"Bulletin Express","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1181474011?lang=en_us&edition=fundamental","pubTime":"2026-05-28 06:42","pubTimestamp":1779921770,"startTime":"0","endTime":"0","summary":"On 28 May 2026, Suzhou Ribo Life Science Co., Ltd. (Ribo Life Science) announced the submission of a Phase II clinical trial application for its self-developed RBD1119 Injection to the European...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182573492","title":"Soochow Securities Reiterates \"Buy\" Rating on RIBOLIFE-B (06938) Citing Advancements in Extrabepatic Delivery Technology","url":"https://stock-news.laohu8.com/highlight/detail?id=1182573492","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1182573492?lang=en_us&edition=fundamental","pubTime":"2026-05-20 14:54","pubTimestamp":1779260076,"startTime":"0","endTime":"0","summary":"Soochow Securities Company Limited. has released a research report maintaining a \"Buy\" rating on RIBOLIFE-B (06938). The report notes that the company's current revenue primarily stems from milestone...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0012","BK0188","BK1161","601555","BK0028","BK0009","06938","BK0276","BK0183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100532115","title":"Registration Open for \"Zhihui Financial 2026 Summer Roadshow Conference\"","url":"https://stock-news.laohu8.com/highlight/detail?id=1100532115","media":"Stock News","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1100532115?lang=en_us&edition=fundamental","pubTime":"2026-05-18 10:47","pubTimestamp":1779072449,"startTime":"0","endTime":"0","summary":"In the first half of 2026, the Hong Kong capital market is experiencing a long-awaited period of heightened activity. Since the second quarter, the Hong Kong market has been on a sustained recovery...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1144","BK1109","BK1539","03881","BK1117","03317","01378","BK1161","02142","LU0359202008.SGD","BK4588","01300","LU1303224171.USD","00290","BK1229","02670","BK1594","LU0588546209.SGD","00363","01021","LU0737861699.HKD","02685","02526","VXUS","BK1506","LU0572940350.SGD","BK1500","BK1147","LU1166156734.SGD","SG9999014674.SGD","BK1617","02228","02411","LU0702159699.USD","06636","08299","BK1613","LU0359201612.USD","02729","LU1023057109.AUD","02655","02575","BK1171","HK0001040143.USD","BK1191","02726","06051","BK1162","02652","BK1155","LU0314109678.HKD","BK1100","LU0287142896.SGD","LU0630314457.HKD","BK1592","02659","02623","BK1207","LU1328277881.USD","LU1719994722.HKD","LU0307460666.USD","00305","01396","BK1578","06938","06090","01333","LU1770034418.SGD","LU0345780950.USD","BK1238","BK1240","BK1149","BK1169","06651","BK1541","LU0359201885.HKD","LU0469268626.HKD","02565","BK4585","BK1116","BK1249","01907","LU1224709979.USD","BK1132","BK1175","BK1142","BK1230","BK1258","LU1813983027.USD","BK1183","02675","02889","00826","00650","02706","BK1198","02650","BK1129","HK0001040168.HKD","BK1110","SG9999001093.SGD","BK1225","LU0572939691.SGD","LU0173614495.USD","BK1190","LU2039709279.SGD","BK1163","BK1205","01384","06682","09696","03858","BK1583","LU0345781412.USD","LU1251922891.USD","BK1141","LU0264606111.USD","BK1574","00400"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635737710","title":"Ribo signs strategic collaboration with Insilico Medicine on AI-driven siRNA drugs","url":"https://stock-news.laohu8.com/highlight/detail?id=2635737710","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635737710?lang=en_us&edition=fundamental","pubTime":"2026-05-14 03:06","pubTimestamp":1778699191,"startTime":"0","endTime":"0","summary":"Suzhou Ribo Life Science entered strategic collaboration agreement with Insilico Medicine on May 13, 2026 to speed development of AI-enabled siRNA drugs.Partnership targets joint work on therapeutic target identification, siRNA drug design and optimization, AI-assisted development, clinical translation.Deal builds on earlier collaboration in autonomous high-throughput intelligent screening, with Insilico platform Pharma.AI slated to support oligonucleotide development programs.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nNDLbBnc6P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634211380","title":"Insilico Medicine partners with Ribo Life Science on AI-driven oligonucleotide R&D","url":"https://stock-news.laohu8.com/highlight/detail?id=2634211380","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634211380?lang=en_us&edition=fundamental","pubTime":"2026-05-12 20:32","pubTimestamp":1778589161,"startTime":"0","endTime":"0","summary":"Insilico Medicine Cayman Topco entered strategic collaboration agreement with Suzhou Ribo Life Science to expand joint work on RNA interference and oligonucleotide therapeutics development.Deal pairs Insilico Pharma.AI drug discovery platform with Ribo oligonucleotide development capabilities, targeting faster end-to-end R&D execution.Cooperation builds on existing experimental services work tied to Insilico LifeStar 2 automated laboratory, where Ribo is first high-throughput services partner.Ribo cited prior partnerships valued at more than USD 6 billion, positioning collaboration as part of its broader business development strategy.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nNDL7dXJ27:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938","BK1141","BK1161","03696"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634321904","title":"Ribo Announces Strategic Collaboration With Insilico Medicine to Accelerate Sirna Drug Development Driven by AI","url":"https://stock-news.laohu8.com/highlight/detail?id=2634321904","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634321904?lang=en_us&edition=fundamental","pubTime":"2026-05-12 20:30","pubTimestamp":1778589006,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nTUA92YYHJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["06938","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111399529","title":"瑞博生物发布H股股权激励方案：股份总量上限17.06 million，占总股本10%","url":"https://stock-news.laohu8.com/highlight/detail?id=1111399529","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1111399529?lang=en_us&edition=fundamental","pubTime":"2026-05-12 18:23","pubTimestamp":1778581422,"startTime":"0","endTime":"0","summary":"苏州瑞博生物技术股份有限公司（瑞博生物）公布《H股股份激励计划》，并已提交股东大会特别决议案审批。以下为方案要点： 1. 计划规模与期限   • 计划总量：可新发行及/或由受托人购入的H股不超过17.06 million 股，占采纳日已发行股份的10%。   • 服务提供者专属子限额：0.85 million 股，占已发行股份的0.5%。   •...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107643960","title":"瑞博生物发布H股购股权计划：期权总量上限约1,705.55万股，占已发行股本10%","url":"https://stock-news.laohu8.com/highlight/detail?id=1107643960","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1107643960?lang=en_us&edition=fundamental","pubTime":"2026-05-12 18:23","pubTimestamp":1778581420,"startTime":"0","endTime":"0","summary":"Suzhou Ribo Biotechnology Co., Ltd.（瑞博生物，H股简称：RIBOLIFE-B）公布《H股购股权计划》草案，方案已提交股东大会审议，通过后即生效并执行期为10年。 核心条款   1. 期权池规模：本计划与其他任何股份激励计划下可发行的合计股份数上限为17,055,491股，对应当前已发行股本的10.00%。   2....","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147632196","title":"RIBOLIFE-B Calls 5 June 2026 AGM; Tables Option & Incentive Schemes, Scraps Supervisory Committee and Seeks Fresh Mandates","url":"https://stock-news.laohu8.com/highlight/detail?id=1147632196","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1147632196?lang=en_us&edition=fundamental","pubTime":"2026-05-12 18:23","pubTimestamp":1778581418,"startTime":"0","endTime":"0","summary":"Suzhou Ribo Life Science Co., Ltd. (“RIBOLIFE-B”) has issued a circular convening its annual general meeting for 1:30 p.m. on 5 June 2026 in Beijing.  Key proposals and information are summarised...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192874107","title":"Ribo Life Science releases proxy details for 2025 AGM; shareholders to vote on profit distribution, equity incentives and governance overhaul","url":"https://stock-news.laohu8.com/highlight/detail?id=1192874107","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1192874107?lang=en_us&edition=fundamental","pubTime":"2026-05-12 18:23","pubTimestamp":1778581394,"startTime":"0","endTime":"0","summary":"Suzhou Ribo Life Science Co., Ltd. has circulated the proxy form for its 2025 Annual General Meeting, which will convene at 1:30 p.m. on Friday, 5 June 2026 at F3, 3B-2 China Resources Life Sciences...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634292585","title":"Suzhou Ribo Life Science announces annual shareholder meeting rescheduling","url":"https://stock-news.laohu8.com/highlight/detail?id=2634292585","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634292585?lang=en_us&edition=fundamental","pubTime":"2026-05-12 17:46","pubTimestamp":1778579201,"startTime":"0","endTime":"0","summary":"Suzhou Ribo Life Science will hold its rescheduled annual general meeting in Hong Kong on June 5, 2026.Meeting date was moved from June 9 due to administrative reasons.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Suzhou Ribo Life Science Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on May 12, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nNDL8WT1zD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634780283","title":"Suzhou Ribo Seeks Venous Thromboembolism Drug Trial in Europe","url":"https://stock-news.laohu8.com/highlight/detail?id=2634780283","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634780283?lang=en_us&edition=fundamental","pubTime":"2026-05-11 19:20","pubTimestamp":1778498424,"startTime":"0","endTime":"0","summary":"Suzhou Ribo Life Science (HKG:6938) submitted a phase 2b clinical trial application for Vortosiran at the European Medicines Agency (EMA), according to a Monday Hong Kong bourse filing.The trial aims to study the drug for the prevention of venous thromboembolism.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["EMA.AU","BK4081","06938","BK7129","EMA","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112507773","title":"RIBOLIFE-B's Core Product Vortosiran Submits Phase 2b Clinical Trial Application for Venous Thromboembolism","url":"https://stock-news.laohu8.com/highlight/detail?id=1112507773","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1112507773?lang=en_us&edition=fundamental","pubTime":"2026-05-11 17:47","pubTimestamp":1778492820,"startTime":"0","endTime":"0","summary":"RIBOLIFE-B (06938) announced that its core product, vortosiran (RBD4059), has successfully submitted a Phase 2b Clinical Trial Application (CTA) to the European Medicines Agency (EMA) for the...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156882324","title":"RIBOLIFE-B Advances Core siRNA Therapy: Submits Phase 2b European Trial Application for Vortosiran in Venous Thromboembolism","url":"https://stock-news.laohu8.com/highlight/detail?id=1156882324","media":"Bulletin Express","labels":["corporation","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1156882324?lang=en_us&edition=fundamental","pubTime":"2026-05-11 17:44","pubTimestamp":1778492646,"startTime":"0","endTime":"0","summary":"Suzhou Ribo Life Science Co., Ltd. (RIBOLIFE-B) has filed a Phase 2b clinical-trial application (CTA) with the European Medicines Agency for vortosiran (RBD4059), its lead small-interfering RNA...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":1,"totalSize":92,"code":"91000000","status":"200"}]}}